score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61L	0.4646	254.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0.0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0				NRAS p.Q61L (Missense)	1.0	MEL-IPI_Pat170	MEL-IPI_Pat170-Tumor-SM-5VOAZ	MEL-IPI_Pat170-Normal-SM-5VWIU
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.Q317*	0.4138	29.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0.0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0				TP53 p.Q317* (Nonsense)		MEL-IPI_Pat170	MEL-IPI_Pat170-Tumor-SM-5VOAZ	MEL-IPI_Pat170-Normal-SM-5VWIU
Investigate Actionability			Inferential	Aneuploidy	Whole genome doubling																						Investigate Actionability	0.0	WGD was associated with adverse survival pan-cancer in patients with advanced disease and in cancers with heterogeneous clinical outcomes, even following the development of metastasis.	Bielski CM, Zehir A, Penson AV, et al. Genome doubling shapes the evolution and prognosis of advanced cancers Nat Genet. 2018; 50(8):1189-1195.	https://doi.org/10.1038/s41588-018-0165-1	0						MEL-IPI_Pat170		
Investigate Actionability	FDA-Approved			Somatic Variant	RAD51B	Missense	p.D186N	0.2088	182.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf													0				RAD51B p.D186N (Missense)	0.0	MEL-IPI_Pat170	MEL-IPI_Pat170-Tumor-SM-5VOAZ	MEL-IPI_Pat170-Normal-SM-5VWIU
Investigate Actionability	Preclinical			Copy Number	FGFR1	Deletion				0.0	0.0		Investigate Actionability	Infigratinib	FGFR inhibition	Targeted therapy	A study of 32 Cancer Cell Line Encyclopedia cell lines demonstrating FGFR1 and FGFR2 amplification demonstrated sensitivity to Infigratinib.	Guagnano V, Kauffmann A, Wohrle S, et al. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov. 2012;2(12):1118-33.	https://doi.org/10.1158/2159-8290.CD-12-0210													0				FGFR1 Deletion		MEL-IPI_Pat170	MEL-IPI_Pat170-Tumor-SM-5VOAZ	
Investigate Actionability	Inferential			Copy Number	CD274	Deletion				0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PD-L1 expression in at least 50% of tumor cells correlated with improved efficacy of pembrolizumab in a trial of 495 patients with non-small cell lung cancer. 	Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018-28.	https://doi.org/10.1056/NEJMoa1501824													0				CD274 Deletion		MEL-IPI_Pat170	MEL-IPI_Pat170-Tumor-SM-5VOAZ	
Biologically Relevant				Copy Number	EWSR1	Amplification				0.0	0.0																					0				EWSR1 Amplification		MEL-IPI_Pat170	MEL-IPI_Pat170-Tumor-SM-5VOAZ	
Biologically Relevant				Copy Number	RAD51D	Deletion				0.0	0.0																					0				RAD51D Deletion		MEL-IPI_Pat170	MEL-IPI_Pat170-Tumor-SM-5VOAZ	
Biologically Relevant				Copy Number	JAK2	Deletion				0.0	0.0																					0				JAK2 Deletion		MEL-IPI_Pat170	MEL-IPI_Pat170-Tumor-SM-5VOAZ	
Biologically Relevant				Copy Number	FLI1	Deletion				0.0	0.0																					0				FLI1 Deletion		MEL-IPI_Pat170	MEL-IPI_Pat170-Tumor-SM-5VOAZ	
Biologically Relevant				Copy Number	ROS1	Deletion				0.0	0.0																					0				ROS1 Deletion		MEL-IPI_Pat170	MEL-IPI_Pat170-Tumor-SM-5VOAZ	
Biologically Relevant				Mutational Signature	COSMIC Signature 7	version 2	0.791																									0				COSMIC Signature (version 2) 7 (79%)		MEL-IPI_Pat170		
